Delving into the Latest Updates on Desoximetasone with Synapse

Psoriasis and atopic dermatitis are chronic inflammatory disease that account for a significant amount of patients in most dermatological practices. Topical corticosteroid agents are often prescribed for treatment of both these conditions, especially when they are localized rather than wide spread. The development of resistance to treatment is termed tachyphylaxis. Poor adherence, rather than down regulation of receptors, may be the primary cause of tachyphylaxis to topical corticosteroids. The primary objective of the study is to determine, under conditions designed to assure good adherence, whether topical 0.25% desoximetasone spray improves clinical outcomes in patients who have resistant inflammatory skin disease defined by failure of previous topical steroid treatment.

Start Date01 Feb 2017

Sponsor / Collaborator

Wake Forest School of Medicine

NCT02932878

/ CompletedPhase 2

An Open Label, Safety Study to Assess the Potential for Adrenal Suppression Following Treatment With DSXS Topical Product in Patients With Plaque Psoriasis

An Open Label, Safety Study to Assess the Potential for Adrenal Suppression Following Treatment with DSXS (Taro Pharmaceuticals U.S.A., Inc.) in Patients with Plaque Psoriasis

Start Date02 Sep 2016

Sponsor / Collaborator

Taro Pharmaceuticals U.S.A., Inc.

NCT02985736

/ CompletedPhase 4IIT

An Open-Label, Study Evaluating Topicort® Topical Spray 0.25% (Desoximetasone) in Patients With Scalp Psoriasis

A single center, study of 20 subjects to assess 4 weeks of therapy with Topicort® twice daily BID and 12 weeks twice daily on 2 consecutive days to patients with scalp psoriasis

Start Date01 Sep 2016

Sponsor / Collaborator

Taro Pharmaceuticals U.S.A., Inc.

100 Clinical Results associated with Desoximetasone

Login to view more data

100 Translational Medicine associated with Desoximetasone

Login to view more data

100 Patents (Medical) associated with Desoximetasone

Login to view more data

323

Literatures (Medical) associated with Desoximetasone

01 May 2025·Biomedicine & Pharmacotherapy

Sakuranetin modulates IL-17A-related inflammation and enhances skin barrier function in an imiquimod-induced psoriasis model

Article

Author: Cheng, Yu-Ping ; Wang, Tzu-Ming ; Lai, Chien-Yu ; Chen, Yung-Chuan ; Wang, Wei-Chin ; Guo, Jiun-Wen ; Liu, Chih-Yi

Sakuranetin, a methoxylated flavanone with known anti-inflammatory and antioxidant properties, has yet to be explored for its therapeutic potential in psoriasis treatment. This study evaluates its efficacy in an imiquimod-induced psoriasis-like murine model, focusing on both immune modulation and skin barrier restoration. Topical administration of sakuranetin significantly attenuated psoriatic inflammation, with high-dose treatment achieving comparable efficacy to desoximetasone. RNA sequencing and qPCR validation revealed that sakuranetin modulates keratinization, cornified envelope formation, and kallikrein-related peptidase activity, suggesting its role in epidermal homeostasis. Notably, sakuranetin selectively downregulated IL-17A while maintaining IL-17F expression, supporting a targeted immunomodulatory effect. Additionally, sakuranetin upregulated KRT1, KRT16, KLK7, Sprr2f, and Wfdc18 while downregulating Sprr2k and Sprr3, indicating a refined regulation of skin barrier proteins. The observed upregulation of Tslp suggests a potential role in epidermal repair mechanisms. These findings highlight sakuranetin as a novel, plant-derived therapeutic candidate with dual anti-inflammatory and skin barrier-enhancing properties, providing a potential corticosteroid-sparing approach for long-term psoriasis management.

01 Apr 2025·Food Chemistry

Unbiased Metabolomic and Chemometric profiles of three Sargassum polycystum extracts using GCMS and LCMS/MS: content analysis, correlation analysis and molecular docking

Article

Author: Lim, Vuanghao ; Abdulameed, Hassan Taiye ; Alallam, Batoul

Sargassum polycystum (S. polycystum) is a brown macroalga with a high phytochemical content, making it a nutritious and bioactive food source. However, information on factors contributing to health benefits, like antioxidants and cytotoxicity, is less explored for Malaysian S. polycystum. In this study, three extracts of S. polycystum were characterized using a combination of analytical techniques. Despite similar carbohydrate content across all extracts, water extract exhibited the highest protein [21.90 ± 1.01 albumin equivalent (μg/mg)] and phenolic [7.73 ± 1.95 gallic acid equivalent (μg/mg)] contents. However, it displayed the lowest antioxidant and anticancer activities [half-maximal inhibitory concentration (IC₅₀) of > 2000 μg/mL]. Interestingly, ethanolic extract demonstrated the strongest scavenging activity (IC₅₀ of 397.90 ± 20.43 μg/mL) and selective anticancer activity against MCF7 breast cancer cells (IC₅₀ of 338.63 ± 48.98 μg/mL). Untargeted metabolomic profiling confirmed the differences in the chemical composition of the extracts. Subsequently, correlation and docking analyses were used to identify the potential bioactive compounds within the extracts. The ethanolic extract is a rich source of these bioactive compounds with superior antioxidant and anticancer properties, highlighting the need for further research on its potential utility in the food industry.

01 Sep 2024·Journal of the European Academy of Dermatology and Venereology

Association between maternal dupilumab exposure and pregnancy outcomes in patients with moderate‐to‐severe atopic dermatitis: A nationwide retrospective cohort study

Article

Author: Costanzo, Antonio ; Roccuzzo, Gabriele ; Loi, Camilla ; Balato, Anna ; Mastorino, Luca ; Ferrucci, Silvia M ; Russo, Filomena ; Mercuri, Santo R ; Potenza, Concetta ; Marozio, Luca ; Nettis, Eustachio ; Patruno, Cataldo ; Zalaudek, Iris ; Ortoncelli, Michela ; Marzano, Angelo V ; Argenziano, Giuseppe ; Gargiulo, Luigi ; Parodi, Aurora ; Trave, Ilaria ; Napolitano, Maddalena ; Silvio, Martina ; Ribero, Simone ; Di Nicola, Matteo R ; Chiricozzi, Andrea ; Bonzano, Laura ; Maronese, Carlo A ; Calabrese, Giulia ; Avallone, Gianluca ; Ferreli, Caterina ; Fraghì, Alessandro ; Cavallo, Francesco ; Gurioli, Carlotta ; Bettolini, Luca ; Quaglino, Pietro ; Gori, Niccolò ; Oddenino, Giorgio A ; Romita, Paolo ; Piras, Viviana ; Rossi, Mariateresa ; Foti, Caterina ; Conforti, Claudio ; Tolino, Ersilia ; Bertello, Martina ; Tancredi, Annalisa ; Gallo, Rosella ; Paolino, Giovanni

AbstractBackgroundThere is limited epidemiological evidence on outcomes associated with dupilumab exposure during pregnancy; monitoring pregnancy outcomes in large populations is required.ObjectiveTo investigate the potential association between exposure to dupilumab in pregnant women with atopic dermatitis and any adverse pregnancy, neonatal, congenital and post‐partum outcomes.MethodsWe performed a multicentre retrospective cohort study across 19 Italian tertiary referral hospital. Childbearing women were eligible if aged 18–49 years and carried out the pregnancy between 1 October 2018 and 1 September 2022.ResultsWe retrospectively screened records of 5062 patients receiving dupilumab regardless of age and gender, identifying 951 female atopic dermatitis patients of childbearing age, 29 of whom had been exposed to the drug during pregnancy (3%). The median duration of dupilumab treatment prior to conception was 22.5 weeks (range: 3–118). The median time of exposure to the drug during pregnancy was 6 weeks (range: 2–24). All the documented pregnancies were unplanned, and the drug was discontinued in all cases once pregnancy status was reported. The comparison of the study cohort and the control group found no significant drug‐associated risk for adverse pregnancy, congenital, neonatal or post‐partum outcomes. The absence of a statistically significant effect of exposure on the event was confirmed by bivariate analysis and multivariate analysis adjusted for other confounding factors.ConclusionsThis cohort of pregnant patients exposed to dupilumab adds to the existing evidence concerning the safety of biologic agents in pregnancy. No safety issues were identified regarding the primary outcome assessed. In clinical practice, these data provide reassurance in case of dupilumab exposure during the first trimester. However, the continuous use of dupilumab throughout pregnancy warrants further research.

100 Deals associated with Desoximetasone

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D03697	Desoximetasone	D07AC03 D07XC02	DB00547

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Plaque psoriasis	United States	Taro Pharmaceuticals, Inc.	11 Apr 2013
Dermatophilosis	United States	Taro Pharmaceutical Industries Ltd.	17 Jan 1985

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Psoriasis of scalp	Discovery	United States	Taro Pharmaceuticals U.S.A., Inc.	11 Mar 2016
Moderate Atopic Dermatitis	Discovery	United States	Taro Pharmaceuticals U.S.A., Inc.	04 Sep 2015
Severe Atopic Dermatitis	Discovery	United States	Taro Pharmaceuticals U.S.A., Inc.	04 Sep 2015
Plaque psoriasis	Discovery	-	Taro Pharmaceuticals U.S.A., Inc.	01 Aug 2010

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02985736 (CTgov)	Phase 4	Psoriasis of scalp	20	Topicort	sbmfwqglhk(sswgmnnctr) = cnepcwbrcy tuaihuvfra (pcjbwisgts, gabldlrdol - jvumsqxxdu) View more	-	09 Apr 2024
NCT02618759 (CTgov)	Phase 3	Plaque psoriasis	119	Placebo+DSXS (DSXS1505)	ijokuziras(wvdhqdamui) = nvpigdmdnv kfzfoirlff (szamndanwe, plielpnrix - xegdxhamup) View more	-	10 Dec 2018
				Placebo+DSXS (Placebo)	ijokuziras(wvdhqdamui) = xkncwcubii kfzfoirlff (szamndanwe, kkdcqorqcn - piuqxlvxvh) View more
NCT02932891 (CTgov)	Phase 2	Dermatitis, Atopic	28	DSXS	uveyxcnjrl(ttnbsbfvlm) = tmgxvlaode fyspilgiza (aizdwnfbdm, oeehciyfbi - lqkxdgcunh) View more	-	07 Dec 2018
NCT02595073 (CTgov)	Phase 3	Moderate Atopic Dermatitis \| Severe Atopic Dermatitis	124	DSXS (DSXS Topical Product)	dutbhdxzld(rysgesabai) = chlteiyjkz bugpiwrspg (jdkfjsdpaz, ilwxcvjcet - dojhssimmt) View more	-	07 Dec 2018
				Placebo (Placebo Topical Product)	dutbhdxzld(rysgesabai) = kruoosjwor bugpiwrspg (jdkfjsdpaz, ylxsldruet - eabggtoqwf) View more
NCT02595008 (CTgov)	Phase 2	Dermatitis, Atopic	24	DSXS (DSXS Topical Product Cohort 1)	uytcxqgoqt(jsvomxyifv) = jnqllvtlmm avrsliopiz (eakjhsinlg, kzzyjyjpym - anckthrqqy) View more	-	07 Dec 2018
				DSXS (DSXS Topical Product Cohort 2)	uytcxqgoqt(jsvomxyifv) = jpchjwamhf avrsliopiz (eakjhsinlg, adkpmjgweo - uytnjwuomn) View more
NCT02601469 (CTgov)	Phase 2	Plaque psoriasis	26	DSXS (DSXS1503 Cohort 1)	stvecstrig(rmaeatehga) = zopllherkj kmycsqbgkw (amlxdzdphc, elbjypebik - qeyebogarp) View more	-	07 Dec 2018
				DSXS (DSXS1503 Cohort 2)	stvecstrig(rmaeatehga) = uxbowfgbfg kmycsqbgkw (amlxdzdphc, ccjvwhgzyq - oqspzxnqnr) View more
NCT02933528 (CTgov)	Phase 2	Psoriasis of scalp	24	DSXS Topical product	awdfvlcalu(bsnprczsao) = znfcjixcfu uapmwxcfgx (vltkidnopu, rfcunfhqrf - sjofaeudlq) View more	-	06 Dec 2018
NCT02932878 (CTgov)	Phase 2	Plaque psoriasis	16	DSXS (DSXS Topical Cohort 1)	pppyhzvnal(igjdzqqvcs) = nqyfuylirk kfozuqfiuf (qrxkxkvqam, mkaclquzrm - hgqhcpfcmf) View more	-	06 Dec 2018
				DSXS (DSXS Topical Cohort 2)	pppyhzvnal(igjdzqqvcs) = ffhoqqegou kfozuqfiuf (qrxkxkvqam, miovscdvmm - chgmayerow) View more
NCT02933866 (CTgov)	Phase 3	Psoriasis of scalp	371	DSXS topical (DSXS Topical)	qlgexygdxr(ceaspxglnz) = syzbocxxdt hftwfsatxq (wnkclaxjpc, xshqggtzte - wchoeymfif) View more	-	06 Dec 2018
				Vehicle topical (Vehicle Topical)	qlgexygdxr(ceaspxglnz) = ankqebtxxw hftwfsatxq (wnkclaxjpc, pjxaepiwda - rxwdpwgldq) View more
NCT03050294 (CTgov)	Phase 4	Psoriasis \| Dermatitis, Atopic	24	Desoximetasone 0.25% spray (Control- Atopic Dermatitis)	regokmxjap(phuygvleuq) = sxzjjhqtgk nnhtcctktw (etzbakbstx, obwqhnqcsm - mfoktcrllw) View more	-	15 Jun 2018
				Phone calls+Desoximetasone 0.25% spray (Atopic Dermatitis Intervention)	regokmxjap(phuygvleuq) = ablgfwmopz nnhtcctktw (etzbakbstx, jkobrdaqwx - aebvzlierv) View more